SOURCE: NeoStem, Inc.

December 06, 2006 12:23 ET

Pioneer in Anti-Aging Medicine Joins NeoStem Advisory Board

NEW YORK, NY -- (MARKET WIRE) -- December 6, 2006 -- NeoStem, Inc. (OTCBB: NEOI), a company specializing in the collection, processing and long-term storage of Adult Stem Cells (ASCs) for autologous use ("Your cells for your use"), today announced that Ron Rothenberg MD, FACEP, a pioneer in anti-aging medicine, has joined the Company's Advisory Board.

Dr. Rothenberg is a Fellow of the American College of Emergency Physicians (FACEP) and is the founder of the California HealthSpan Institute in Encinitas, California. He was the 10th M.D. in the world to become fully board certified by the American Board of Anti-Aging Medicine. A graduate of Columbia University, College of Physicians and Surgeons, and a specialist in Emergency Medicine at Los Angeles County-USC Medical Center, he has served as Clinical Professor of Preventive and Family Medicine at the UCSD School of Medicine Clinical Facility. He is currently Attending Physician at Scripps Memorial Hospital in Encinitas. (More information regarding Dr. Rothenberg is available at: www.ehealthspan.com and at www.californiaantiaging.com/treatment/bios.asp)

In September 2006, Dr. Rothenberg became the first to join NeoStem's Physician's Network as an Adult Stem Cell Collection Provider, launching a NeoStem Adult Stem Cell Collection Center at his California HealthSpan Institute. Dedicated to the belief that the process of physical aging can be slowed, stopped or even reversed through existing medical and scientific interventions, Dr. Rothenberg believes that adult stem cells can play an important role in emerging anti-aging treatments. He will chair a day-long Workshop and present several lectures at the 14th Annual International Congress on Anti-Aging Medicine taking place in Las Vegas, December 7-10, 2006.

Robin Smith, MD, MBA, NeoStem's Chief Executive Officer, said, "We welcome Dr. Rothenberg to our Advisory Board. He is a leader in the field of Anti-Aging Medicine and Regenerative Biomedical Technologies. We anticipate his medical expertise, together with his experience as the first to join NeoStem's Physician's Network as an Adult Stem Cell Collection Provider, will give the Company important insight as we expand our Physician's Network and develop further centers for the safe collection of adult stem cells to serve a growing range of medical needs."

About NeoStem, Inc.

NeoStem, Inc. (OTCBB: NEOI) is an innovative, publicly traded company positioned to become a leader in the adult stem cell field and to capitalize on the increasing importance adult stem cells are expected to play in the future of regenerative medicine.

Using its proprietary process, NeoStem provides the infrastructure, methods and systems that allow adults to have their stem cells safely collected and conveniently banked for future therapeutic use, as needed, in the treatment of such life-threatening diseases as diabetes, heart disease and radiation sickness that may result from a bio-terrorist attack. Adult stem cell therapy has also been used for many years in treating blood cancer. Further potential uses include regenerative therapies for wound healing, autoimmune diseases such as multiple sclerosis and lupus, and age-related degenerative musculoskeletal diseases.

NeoStem uses the least invasive form of collection called apheresis, a well known safe procedure that extracts stem cells from an adult's peripheral blood. Once collected, NeoStem's storage process allows the cells to be cryo-preserved during an individual's lifetime for use when needed. The management, Board of Directors and Advisors of NeoStem collectively have significant technical, medical and scientific expertise as well as substantial experience in life science marketing and business development.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the Company's ability to develop the adult stem cell business, the future of regenerative medicine and the role of adult stem cells in that future, the future use of adult stem cells as a treatment option and the potential revenue growth of NeoStem's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business and obtain appropriate state licenses; (iii) competitive factors and developments beyond the Company's control;(iv) scientific and medical developments beyond the Company's control and (v) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at www.sec.gov under "Search for Company Filings."

Pursuant to an October 1, 2006 agreement, Consulting For Strategic Growth 1, Ltd. ("CFSG1") provides the Company with consulting, business advisory, investor relations, public relations and corporate development services, for which CFSG1 receives a fixed monthly fee for the duration of the agreement and received shares of NeoStem's common stock. Independent of CFSG1's receipt of cash or other compensation from the Company, CFSG1 may choose to purchase the common stock of the Company and thereafter sell those shares at any time it deems appropriate to do so. For more information, please visit www.cfsg1.com.

Contact Information

  • CONTACTS
    Robin Smith, MD, MBA
    CEO
    NeoStem, Inc.
    420 Lexington Ave, Suite 450
    NYC, NY 10170
    Tel: (212) 584-4180
    Fax: (646) 514-7787
    Email: Email Contact
    Web site: www.neostem.com


    Stanley Wunderlich/Daniel Stepanek
    Consulting for Strategic Growth 1
    800 Second Avenue
    New York, NY 10017
    Tel: (800) 625-2236/ (212) 896-1206
    Fax: (212) 337-8089
    Emails: Email Contact
    Email Contact
    Web site: www.cfsg1.com